Schizophrenia market expected to reach $17bn across 7MM by 2031

Other late-stage pipeline products being investigated as adjunctive agents include Newron Pharmaceuticals’ evenamide, Neurocrine Biosciences’ Ingrezza (valbenazine tosylate) and Boehringer Ingelheim’s iclepertin. As patients would not need to switch from their current therapies, it could greatly help these products establish themselves within the highly competitive and genericised schizophrenia market.

2 Likes

So elon could cover the market for 17 billion and still have 383 billion which would probs make over 17 billion in interest that same year lol.

Cmon elon lend us a few bucks :sweat_smile:

1 Like

We should be getting royalties on this :stuck_out_tongue_closed_eyes:

2 Likes